Biovail Announces Litigation Settlement

December 23, 2008

TORONTO--(BUSINESS WIRE)--Dec. 23, 2008--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a settlement agreement has been reached to resolve all outstanding litigation involving former Banc of America Securities analyst Jerry I. Treppel, including all claims asserted against the Company by Mr. Treppel, and all claims by and against each of Eugene Melnyk and Mr. Treppel. The litigation originally commenced in April 2003.

The terms of the settlement are confidential; however, they are not material to Biovail's cash flows or operating results.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at

www.biovail.com

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com

CONTACT: Biovail Corporation Nelson F. Isabel, (905) 286-3000

Vice-President, Investor Relations and Corporate Communications

Source: Biovail Corporation

Page 1 of 2





LEGAL NOTICE PRIVACY POLICY Investor Inquiries

<u>ir@bauschhealth.com</u>

877-281-6642

514-856-3855 (Canada)

<u>Corporate.communications@bauschhealth.com</u>

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights

reserved. MTB.0230.USA.18 V2.0

908-569-3692

Media inquiries

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

